{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:14:20Z","timestamp":1794489260087,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>\n                    <jats:italic>Abstract<\/jats:italic>\n                  <\/jats:title>\n                  <jats:p>\n                    Idiopathic pulmonary fibrosis (IPF) seriously threatens human life and health, and no curative therapy is available at present. Nintedanib is the first agent approved by the US Food and Drug Administration (FDA) in order to treat IPF; however, its mechanism of inhibition of IPF is still elusive. According to recent studies, nintedanib is a potent inhibitor. It can antagonize platelet-derived growth factor (PDGF), basic fibroblast growth factor (b-FGF), vascular endothelial growth factor (VEGF), etc\n                    <jats:italic>.<\/jats:italic>\n                    , to inhibit pulmonary fibrosis. Whether there are other signaling pathways involved in IPF remains unknown. This study focused on investigating the therapeutic efficacy of nintedanib in bleomycin-mediated pulmonary fibrosis (PF) mice through PI3K\/Akt\/mTOR pathway. Following the induction of pulmonary fibrosis in C57 mice through bleomycin (BLM) administration, the mice were randomized into five groups: (1) the normal control group, (2) the BLM model control group, (3) the low-dose Nintedanib administration model group, (4) the medium-dose nintedanib administration model group, and (5) the high-dose nintedanib administration model group. For lung tissues, morphological changes were found by HE staining and Masson staining, ELISA method was used to detect inflammatory factors, alkaline water method to estimate collagen content, and western blotting for protein levels. TUNEL staining and immunofluorescence methods were used to analyze the effect of nintedanib on lung tissue and the impacts and underlying mechanisms of bleomycin-induced pulmonary fibrosis. After 28\u00a0days, bleomycin-treated mice developed significant pulmonary fibrosis. Relative to bleomycin-treated mice, nintedanib-treated mice had markedly reduced degrees of PF. In addition, nintedanib showed lung-protective effects by up-regulating antioxidant levels, down-regulating inflammatory protein expression, and reducing collagen accumulation. We demonstrated that nintedanib ameliorated bleomycin-induced lung injury by inhibiting the P13K\/Akt\/mTOR pathway as well as apoptosis. In addition, significant improvement in pulmonary fibrosis was seen after nintedanib (30\/60\/120\u00a0mg\/kg body weight\/day) treatment through a dose-dependent way. Histopathological results further corroborated the effect of nintedanib treatment on remarkably attenuating bleomycin-mediated mouse lung injury. According to our findings, nintedanib restores the antioxidant system, suppresses pro-inflammatory factors, and inhibits apoptosis. Nintedanib can reduce bleomycin-induced inflammation by downregulating PI3K\/Akt\/mTOR pathway, PF, and oxidative stress (OS).\n                  <\/jats:p>","DOI":"10.1007\/s10753-023-01825-2","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T17:41:28Z","timestamp":1683740488000},"page":"1531-1542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":141,"title":["Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K\/Akt\/mTOR Pathway in Mice"],"prefix":"10.1007","volume":"46","author":[{"given":"Lin","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiju","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meigui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"1825_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2021.111473","volume":"153","author":"GS Suri","year":"2021","unstructured":"Suri, G.S., G. Kaur, C.K. Jha, and M. Tiwari. 2021. Understanding idiopathic pulmonary fibrosis-clinical features, molecular mechanism and therapies. Experimental Gerontology 153: 111473.","journal-title":"Experimental Gerontology"},{"issue":"7","key":"1825_CR2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1084\/jem.20110551","volume":"208","author":"TA Wynn","year":"2011","unstructured":"Wynn, T.A. 2011. Integrating mechanisms of pulmonary fibrosis. Journal of Experimental Medicine 208 (7): 1339\u20131350.","journal-title":"Journal of Experimental Medicine"},{"issue":"4","key":"1825_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1164\/rccm.201202-0282PP","volume":"186","author":"R Faner","year":"2012","unstructured":"Faner, R., M. Rojas, W. MacNee, and A. Agust\u00ed. 2012. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 186 (4): 306\u2013313.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"1825_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.794997","volume":"12","author":"C Estornut","year":"2021","unstructured":"Estornut, C., J. Milara, M.A. Bayarri, N. Belhadj, and J. Cortijo. 2021. Targeting oxidative stress as a therapeutic approach for idiopathic pulmonary fibrosis. Frontiers in Pharmacology 12: 794997.","journal-title":"Frontiers in Pharmacology"},{"issue":"44 suppl","key":"1825_CR5","doi-asserted-by":"publisher","first-page":"4s","DOI":"10.1183\/09031936.03.00000203a","volume":"22","author":"JD Crapo","year":"2003","unstructured":"Crapo, J.D. 2003. Oxidative stress as an initiator of cytokine release and cell damage. European Respiratory Journal 22 (44 suppl): 4s\u20136s.","journal-title":"European Respiratory Journal"},{"issue":"4","key":"1825_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1164\/rccm.200501-017PP","volume":"172","author":"VL Kinnula","year":"2005","unstructured":"Kinnula, V.L., C.L. Fattman, R.J. Tan, and T.D. Oury. 2005. Oxidative stress in pulmonary fibrosis: A possible role for redox modulatory therapy. American Journal of Respiratory and Critical Care Medicine 172 (4): 417\u2013422.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"12","key":"1825_CR7","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/14728222.2018.1541318","volume":"22","author":"A Hosseinzadeh","year":"2018","unstructured":"Hosseinzadeh, A., S.A. Javad-Moosavi, R.J. Reiter, R. Yarahmadi, H. Ghaznavi, and S. Mehrzadi. 2018. Oxidative\/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis. Expert Opinion on Therapeutic Targets 22 (12): 1049\u20131061.","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"1","key":"1825_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pupt.2006.10.005","volume":"21","author":"ZD Daniil","year":"2008","unstructured":"Daniil, Z.D., E. Papageorgiou, A. Koutsokera, et al. 2008. Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulmonary Pharmacology & Therapeutics 21 (1): 26\u201331.","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"1825_CR9","doi-asserted-by":"crossref","unstructured":"Liu, Z., Y. Wang, H. Zhao, et al. 2014. CB2 receptor activation am eliorates the proinflammatory activity in acute lung injury induced by paraquat.\u00a0BioMed Research International","DOI":"10.1155\/2014\/971750"},{"key":"1825_CR10","doi-asserted-by":"crossref","unstructured":"Ramadurai, D., S. Corder, T. Churney, B. Graney. 2019. A Harshman S Meadows JJ Swigris 2019 Idiopathic pulmonary fibrosis: Educational needs of health-care providers, patients, and caregivers. Chronic Respiratory Disease","DOI":"10.1177\/1479973119858961"},{"issue":"22","key":"1825_CR11","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi, L., R.M. du Bois, G. Raghu, et al. 2014. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New England Journal of Medicine 370 (22): 2071\u20132082.","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"1825_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi, L., U. Costabel, M. Selman, et al. 2011. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. New England Journal of Medicine 365 (12): 1079\u20131087.","journal-title":"New England Journal of Medicine"},{"key":"1825_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12931-014-0157-3","volume":"15","author":"KE Hostettler","year":"2014","unstructured":"Hostettler, K.E., J. Zhong, E. Papakonstantinou, et al. 2014. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respiratory Research 15: 157.","journal-title":"Respiratory Research"},{"issue":"6","key":"1825_CR14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton, R.A., and D.M. Sabatini. 2017. mTOR signaling in growth, metabolism, and disease. Cell 168 (6): 960\u2013976.","journal-title":"Cell"},{"issue":"8","key":"1825_CR15","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1002\/jcp.24351","volume":"228","author":"A Alayev","year":"2013","unstructured":"Alayev, A., and M.K. Holz. 2013. mTOR signaling for biological control and cancer. Journal of Cellular Physiology 228 (8): 1658\u20131664.","journal-title":"Journal of Cellular Physiology"},{"issue":"9","key":"1825_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138625","volume":"10","author":"YS Gui","year":"2015","unstructured":"Gui, Y.S., L. Wang, X. Tian, et al. 2015. mTOR overactivation and compromised autophagy in the pathogenesis of pulmonary fibrosis. PLoS ONE 10 (9): e0138625.","journal-title":"PLoS ONE"},{"issue":"3","key":"1825_CR17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.bbrc.2018.03.039","volume":"498","author":"X Gui","year":"2018","unstructured":"Gui, X., H. Chen, H. Cai, L. Sun, and L. Gu. 2018. Leptin promotes pulmonary fibrosis development by inhibiting autophagy via PI3K\/Akt\/mTOR pathway. Biochemical and Biophysical Research Communications 498 (3): 660\u2013666.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"1825_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12931-018-0829-5","volume":"19","author":"AD Rieg","year":"2018","unstructured":"Rieg, A.D., S. Suleiman, C. Anker, et al. 2018. PDGF-BB regulates the pulmonary vascular tone: Impact of prostaglandins, calcium, MAPK-and PI3K\/AKT\/mTOR signalling and actin polymerisation in pulmonary veins of Guinea pigs. Respiratory Research 19: 120.","journal-title":"Respiratory Research"},{"issue":"4","key":"1825_CR19","first-page":"893","volume":"120","author":"SV Szapiel","year":"1979","unstructured":"Szapiel, S.V., N.A. Elson, J.D. Fulmer, G.W. Hunninghake, and R.G. Crystal. 1979. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. The American Review of Respiratory Disease 120 (4): 893\u2013899.","journal-title":"The American Review of Respiratory Disease"},{"key":"1825_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107798","volume":"222","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo, P., J.A. Kropski, M.G. Jones, et al. 2021. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. Pharmacology & Therapeutics 222: 107798.","journal-title":"Pharmacology & Therapeutics"},{"issue":"3","key":"1825_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.biocel.2007.08.011","volume":"40","author":"A Moeller","year":"2008","unstructured":"Moeller, A., K. Ask, D. Warburton, J. Gauldie, and M. Kolb. 2008. The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? International Journal of Biochemistry & Cell Biology 40 (3): 362\u2013382.","journal-title":"International Journal of Biochemistry & Cell Biology"},{"key":"1825_CR22","first-page":"503","volume":"7","author":"HV Woodcock","year":"2013","unstructured":"Woodcock, H.V., P.L. Molyneaux, and T.M. Maher. 2013. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: Potential of nintedanib. Drug Des Devel Ther. 7: 503.","journal-title":"Drug Des Devel Ther."},{"key":"1825_CR23","first-page":"3374","volume":"187","author":"KE Hostettler","year":"2013","unstructured":"Hostettler, K.E., E. Papakonstantinou, J. Klagas, et al. 2013. Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from patients with idiopathic pulmonary fibrosis and from non-fibrotic controls. American Journal of Respiratory and Critical Care Medicine 187: 3374.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"1825_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/01902148.2020.1738594","volume":"46","author":"E Boxhammer","year":"2020","unstructured":"Boxhammer, E., K. Lehle, C. Schmid, and M. von Suesskind-Schwendi. 2020. Anti-oxidative effect of the tyrosine kinase inhibitor nintedanib: A potential therapy for chronic lung allograft dysfunction? Experimental Lung Research 46 (5): 128\u2013145.","journal-title":"Experimental Lung Research"},{"issue":"11","key":"1825_CR25","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/antiox9111064","volume":"9","author":"AG Fois","year":"2020","unstructured":"Fois, A.G., E. Sotgiu, V. Scano, et al. 2020. Effects of pirfenidone and nintedanib on markers of systemic oxidative stress and inflammation in patients with idiopathic pulmonary fibrosis: A preliminary report. Antioxidants. 9 (11): 1064.","journal-title":"Antioxidants."},{"issue":"7","key":"1825_CR26","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/dvdy.21608","volume":"237","author":"H Kolesov\u00e1","year":"2008","unstructured":"Kolesov\u00e1, H., H. Roelink, and M. Grim. 2008. Sonic hedgehog is required for the assembly and remodeling of branchial arch blood vessels. Developmental Dynamics 237 (7): 1923\u20131934.","journal-title":"Developmental Dynamics"},{"key":"1825_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1755-1536-5-11","volume":"5","author":"NW Todd","year":"2012","unstructured":"Todd, N.W., I.G. Luzina, and S.P. Atamas. 2012. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair. 5: 11.","journal-title":"Fibrogenesis Tissue Repair."},{"issue":"6","key":"1825_CR28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00418-005-0116-7","volume":"125","author":"S Inghilleri","year":"2006","unstructured":"Inghilleri, S., P. Morbini, T. Oggionni, S. Barni, and C. Fenoglio. 2006. In situ assessment of oxidant and nitrogenic stress in bleomycin pulmonary fibrosis. Histochemistry and Cell Biology 125 (6): 661\u2013669.","journal-title":"Histochemistry and Cell Biology"},{"key":"1825_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1289\/ehp.845537","volume":"55","author":"JS Bus","year":"1984","unstructured":"Bus, J.S., and J.E. Gibson. 1984. Paraquat: Model for oxidant-initiated toxicity. Environmental Health Perspectives 55: 37\u201346.","journal-title":"Environmental Health Perspectives"},{"issue":"4","key":"1825_CR30","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1089\/ars.2007.1942","volume":"10","author":"VL Kinnula","year":"2008","unstructured":"Kinnula, V.L., and M. Myll\u00e4rniemi. 2008. Oxidant\u2013antioxidant imbalance as a potential contributor to the progression of human pulmonary fibrosis. Antioxidants & Redox Signaling 10 (4): 727\u2013738.","journal-title":"Antioxidants & Redox Signaling"},{"issue":"12","key":"1825_CR31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/S0891-5849(03)00149-7","volume":"34","author":"B Fubini","year":"2003","unstructured":"Fubini, B., and A. Hubbard. 2003. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radical Biology & Medicine 34 (12): 1507\u20131516.","journal-title":"Free Radical Biology & Medicine"},{"key":"1825_CR32","doi-asserted-by":"publisher","first-page":"41082","DOI":"10.1038\/srep41082","volume":"7","author":"C Zhang","year":"2017","unstructured":"Zhang, C., C. Li, S. Chen, et al. 2017. Hormetic effect of panaxatriol saponins confers neuroprotection in PC12 cells and zebrafish through PI3K\/AKT\/mTOR and AMPK\/SIRT1\/FOXO3 pathways. Science and Reports 7: 41082.","journal-title":"Science and Reports"},{"issue":"5","key":"1825_CR33","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.3892\/ol.2016.5213","volume":"12","author":"L Yang","year":"2016","unstructured":"Yang, L., Y. Liu, M. Wang, et al. 2016. Celastrus orbiculatus extract triggers apoptosis and autophagy via PI3K\/Akt\/mTOR inhibition in human colorectal cancer cells. Oncology Letters 12 (5): 3771\u20133778.","journal-title":"Oncology Letters"},{"issue":"6","key":"1825_CR34","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/acel.12514","volume":"15","author":"Y Romero","year":"2016","unstructured":"Romero, Y., M. Bueno, R. Ramirez, et al. 2016. mTORC 1 activation decreases autophagy in aging and idiopathic pulmonary fibrosis and contributes to apoptosis resistance in IPF fibroblasts. Aging Cell 15 (6): 1103\u20131112.","journal-title":"Aging Cell"},{"issue":"1","key":"1825_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.apsb.2021.07.023","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang, J., K. Hu, X. Cai, et al. 2021. Targeting PI3K\/AKT signaling for treatment of idiopathic pulmonary fibrosis. Acta Pharm Sin B. 12 (1): 18\u201332.","journal-title":"Acta Pharm Sin B."},{"issue":"1","key":"1825_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bbcan.2017.03.002","volume":"1868","author":"JM Spangle","year":"2017","unstructured":"Spangle, J.M., T.M. Roberts, and J.J. Zhao. 2017. The emerging role of PI3K\/AKT-mediated epigenetic regulation in cancer. Biochimica et Biophysica Acta - Reviews on Cancer 1868 (1): 123\u2013131.","journal-title":"Biochimica et Biophysica Acta - Reviews on Cancer"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-023-01825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-023-01825-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-023-01825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T03:14:32Z","timestamp":1689822872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-023-01825-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1007\/s10753-023-01825-2","relation":{},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"16 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This animal experiment was carried out in strict accordance with the Guidelines for the Care and Use of Laboratory Animals issued by the National Institutes of Health and the regulations of the Animal Ethics Experiment Committee of Guizhou Medical University (approval number: Qian 2101424).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}